Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Gemcitabine and Carboplatin for Metastatic Triple-Negative Breast Cancer (TNBC)
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: TNBC - Triple-Negative Breast Cancer|Breast Cancer
Interventions: DRUG: Trilaciclib|DRUG: Placebo|DRUG: Gemcitabine|DRUG: Carboplatin
Sponsor: G1 Therapeutics, Inc.